The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 06, 2023

Filed:

Sep. 27, 2018
Applicant:

Hualan Genetic Engineering Co., Ltd., Xinxiang, CN;

Inventors:

Xiaoqi Song, Suzhou, CN;

Zui Chen, Suzhou, CN;

Hongqun Hu, Suzhou, CN;

Guifang Zhou, Suzhou, CN;

Jinling Fan, Suzhou, CN;

Qunmin Zhou, Suzhou, CN;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); C07K 16/22 (2006.01); C07K 16/42 (2006.01); C12N 15/10 (2006.01); C12N 15/63 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6803 (2017.08); C07K 16/22 (2013.01); C07K 16/4241 (2013.01); C12N 15/101 (2013.01); C12N 15/63 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01);
Abstract

Disclosed herein is a monoclonal antibody or a derivative thereof that specifically binds to human plasmalemma vesicle-associated protein (PLVAP, PV-1), including antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody light chain variable region, and antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody heavy chain variable region. The invention also provides a preparation process of a human-mouse chimeric antibody and amino acid sequences of the antibody heavy chain variable region and the antibody light chain variable region. The monoclonal antibody or derivative thereof can be used as a component of a pharmaceutical composition or prepared into a suitable medicament, administered alone or combined with other medications such as anti-VEGF monoclonal antibody and the like, for treating choroidal neovascularization fundus diseases and other angiogenesis/osmosis-related diseases.


Find Patent Forward Citations

Loading…